Cargando…
DRUGGABLE MM THERAPEUTICS: PATHOGENETIC PATHWAYS
Autor principal: | Ocio, Enrique M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009784/ http://dx.doi.org/10.1097/01.HS9.0000829496.38330.41 |
Ejemplares similares
-
TREATMENT OF TRIPLE-CLASS REFRACTORY DISEASE: BEYOND IMMUNOTHERAPY
por: Gavriatopoulou, M.
Publicado: (2023) -
LIGHT CHAIN DEPOSITION DISEASE
por: Vos, Josephine M.I.
Publicado: (2022) -
MASS SPECTROMETRY AS A TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION IN THE BLOOD OF MYELOMA PATIENTS
por: Jacobs, J.F.M.
Publicado: (2023) -
COVID-19 AND MYELOMA
por: Ludwig, H, et al.
Publicado: (2022) -
HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)